The Latest Breaking News from UnitedHealthcare

Despite the Fed's aggressive interest rate hikes, the job market remains strong. However, given the mounting recessionary fears, it may be prudent to invest in UnitedHealth Group (UNH) and Biogen (BIIB), based on their solid fundamentals and impressive growth prospects. Continue Reading….

Health care providers, nursing home representatives and patient advocates say Medicare Advantage plans increasingly are ending members’ coverage for nursing home and rehabilitation services before patients are healthy enough to go home.

The bear market is creating a challenging environment for investors. One place to find outperformance could be high0-quality, healthcare stocks that are paying a dividend. Therefore, investors should consider dividend-paying healthcare stocks like Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), and Unitedhealth Group (UNH).   .

While the stock market has entered a bear phase following the release of multi-decade high inflation data, the health insurance industry could survive the downturn because of the near-inelastic demand for health coverage. Therefore, investors looking to dodge a market downturn could bet on fundamentally sound health insurance stocks Anthem…

CHICAGO -- Some Illinois residents say they’re still having trouble getting free at-home COVID-19 tests from pharmacies and insurance companies, more than three months after the White House began requiring insurers to cover them.

Despite volatile market conditions owing to the Russia-Ukraine war, supply chain bottlenecks, high inflation, and imminent aggressive federal interest rate increases, the Dow Jones Industrial Average has managed to advance over the past month on an improving labor market and strong corporate results. So, we think it could be wise…

UnitedHealth Group Inc (NYSE: UNH) 

UnitedHealth Group is paying $5.4 billion to acquire LHC Group, a Louisiana-based home care company, in a deal that pushes the Minnetonka-based health care giant further into direct patient care.

UnitedHealthcare has added Kala Pharmaceuticals Inc's (NASDAQ:KALA) Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies effective March 2022.  Eysuvis now has coverage for approximately 118 million lives or 70% of all commercial lives. Kala also announced that Cigna Medicare had added Eysuvis as a preferred brand effective…